Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

648
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
648
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
Drug Therapy01:28

Drug Therapy

185
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
185
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

824
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
824
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

250
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
250

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dissociable, species-specific impact of Aβ on static and dynamic functional connectomes.

bioRxiv : the preprint server for biology·2026
Same author

Voice and Speech in Atypical Parkinsonian Disorders.

Movement disorders clinical practice·2026
Same author

Optogenetic inhibition reveals distinct contributions of medial prefrontal cortex to intertemporal choice in young and aged rats.

Cerebral cortex (New York, N.Y. : 1991)·2025
Same author

Optogenetic inhibition reveals distinct contributions of medial prefrontal cortex to intertemporal choice in young and aged rats.

bioRxiv : the preprint server for biology·2025
Same author

Fixel-Based Analysis of Diffusion Imaging as a Quantitative Marker of Disease State in Spinocerebellar Ataxia.

Annals of clinical and translational neurology·2025
Same author

Single-cell multiomics identifies both shared and unique features of immune dysfunction in Parkinson's disease and inflammatory bowel disease colon, plasma and stool.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Dec 12, 2025

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.9K

Current Management and Emerging Therapies in Multiple System Atrophy.

Matthew R Burns1, Nikolaus R McFarland2

  • 1Norman Fixel Institute for Neurological Diseases at UFHealth, Movement Disorders Division, Department of Neurology, University of Florida, 3009 SW Williston Rd, Gainesville, FL, 32608, USA.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|August 9, 2020
PubMed
Summary

Multiple system atrophy (MSA) is a progressive neurodegenerative disease impacting motor, nonmotor, and autonomic functions. Current management focuses on multidisciplinary care, while research explores disease-modifying therapies like synuclein-targeted treatments.

Keywords:
Multiple system atrophydisease-modifyingmultidisciplinary caresymptomatic therapyα-synuclein

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.4K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.0K

Related Experiment Videos

Last Updated: Dec 12, 2025

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.9K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.4K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.0K

Area of Science:

  • Neurodegenerative diseases
  • Autonomic dysfunction
  • Oligodendrocyte pathology

Background:

  • Multiple system atrophy (MSA) is a progressive neurodegenerative disorder.
  • Characterized by motor, nonmotor, and autonomic symptoms due to putaminal and cerebellar degeneration.
  • Pathology involves glial cytoplasmic inclusions with α-synuclein in oligodendrocytes.

Purpose of the Study:

  • To review current management strategies for Multiple System Atrophy (MSA).
  • To discuss emerging therapies for MSA.
  • To highlight the importance of a multidisciplinary approach in managing MSA.

Main Methods:

  • Literature review of current and emerging treatments for MSA.
  • Analysis of the impact of symptoms on quality of life.
  • Focus on synuclein-targeted therapies and other disease-modifying approaches.

Main Results:

  • Symptomatic treatments offer partial quality of life improvements but do not address the underlying cause.
  • A multidisciplinary approach, patient-centered care is crucial for managing MSA.
  • Research into disease-modifying therapies, particularly those targeting α-synuclein, is ongoing.

Conclusions:

  • Effective management of MSA requires a coordinated, multidisciplinary approach tailored to patient priorities.
  • While symptomatic treatments provide some relief, the development of disease-modifying therapies is critical.
  • Ongoing research offers hope for more effective treatments for Multiple System Atrophy.